anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Stroke is one of the main reasons of mortality and morbidity all over the world. In economically developed countries stroke takes 2 or 3 place in the structure of morbidity and mortality. In animal models, it was shown that autological stem cells transplantation significantly increased perfusion of ischemic area and improved lost motor and sensor functions. Granulocyte-colony stimulating factor (G-CSF) was used in some clinical trials without following autological transplantation. However, there are no enough evidence-based proved results of G-GSF safety and effectiveness in acute ischemic stroke. In order to determine safety and efficiency of G-CSF administration together with conventional treatment and conventional intensive care protocol during acute ischemic stroke we organized this clinical trial.
Subjects will wear a harness attached to a system to provide body weight support and they will walk on a treadmill with the help of a robotic-driven gait orthosis. The legs are guided according to a physiological gait pattern. The torque of the knee and hip drives can be adjusted from 100% to 0% for one or both legs. The speed of the treadmill can be adjusted from 0 km/h to approximately 3 km/h and body weight support from 0% to 100%. Training sessions will last for an hour with 30 minutes of real walking time, because subject set-up in the device take approximately 30 minutes.
Arformoterol tartrate inhalation solution should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition. The use of arformoterol tartrate inhalation solution in this setting is inappropriate.

Arformoterol tartrate inhalation solution is not indicated for the treatment of acute episodes of bronchospasm, i.e., as rescue therapy and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

When beginning arformoterol tartrate inhalation solution, patients who have been taking inhaled short-acting beta2-agonists on a regular basis (e.g., four times a day) should be instructed to discontinue the regular use of these drugs and use them only for symptomatic relief of acute respiratory symptoms. When prescribing arformoterol tartrate inhalation solution, the healthcare provider should also prescribe an inhaled, short-acting beta2-agonist and instruct the patient how it should be used. Increasing inhaled beta2-agonist use is a signal of deteriorating disease for which prompt medical attention is indicated. COPD may deteriorate acutely over a period of hours or chronically over several days or longer. If arformoterol tartrate inhalation solution no longer controls the symptoms of bronchoconstriction, or the patient's inhaled, short-acting beta2-agonist becomes less effective or the patient needs more inhalation of short-acting beta2-agonist than usual, these may be markers of deterioration of disease. In this setting, a reevaluation of the patient and the COPD treatment regimen should be undertaken at once. Increasing the daily dosage of arformoterol tartrate inhalation solution beyond the recommended 15 mcg twice daily dose is not appropriate in this situation.
NEW MATERIAL:A compound of formula I (R<1>, R<2> and R<3> are 1-4C alkyl). EXAMPLE:Dimethyl 4-methyl-4-hydroxy-1,3-dithiolan-2-ylidenemalonate. USE:A remedy for hepatic diseases, having diuretic action and reducing action on alcoholic concentration in blood, etc., and exhibiting remarkable inhibitory action on hepatic disorder as compared with a group administered with carbon tetrachloride alone with very low toxicity. PROCESS:A malonic acid ester of formula II is reacted with CS2 in the presence of a base to give a dialkali 2,2-bis(alkoxycarbonyl)ethylene-1,1-dithiolate of formula III (M is alkali metal), which is then reacted with an alpha-haloketone of formula IV (X is halogen) in the presence of an inert solvent, e.g. benzene, and an acid, e.g. acetic acid, at 50 deg.C or below to afford the aimed compound of formula I .
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In the two clinical trials with MPA Injectable Suspension, USP, over 3,900 women, who were treated for up to 7 years, reported the following adverse reactions, which may or may not be related to the use of MPA Injectable Suspension, USP. The population studied ranges in age from 15 to 51 years, of which 46% were White, 50% Non-White, and 4.9% Unknown race. The patients received 150 mg MPA Injectable Suspension, USP every 3-months (90 days). The median study duration was 13 months with a range of 1–84 months. Fifty eight percent of patients remained in the study after 13 months and 34% after 24 months.

Adverse reactions leading to study discontinuation in ≥2% of subjects: bleeding (8.2%), amenorrhea (2.1%), weight gain (2.0%)
PURPOSE: A pharmaceutical composition for prevention or treatment of cancer containing Lysimachia foenum-graecum extract is provided to have the low possibility to cause a side effect as the active ingredient is derived from a natural substance, and to be able to be usefully used for prevention, treatment and alleviation of cancer as the composition has no cytotoxicity. CONSTITUTION: A pharmaceutical composition for prevention or treatment of cancer contains Lysimachia foenum-graecum extract as an active ingredient. The Lysimachia foenum-graecum extract is ethanol extract of Lysimachia foenum-graecum. The ethanol extract of Lysimachia foenum-graecum is ethanol extract of pH 3-pH 11. Said cancer is breast cancer, colon cancer, skin cancer or liver cancer. Food for prevention or alleviation of cancer contains Lysimachia foenum-graecum extract as an active ingredient. [Reference numerals] (AA) MCF-7, Lysimachia davurica pH 3, 6 h
OBJECTIVE: There is mounting evidence indicating that atherosclerosis represents a persistent inflammatory process, characterized by the presence of inflammation at various stages of the disease. Interleukin-1 (IL-1) precisely triggers inflammatory signaling pathways by binding to interleukin-1 receptor type I (IL-1R1). Inhibition of this signaling pathway contributes to the prevention of atherosclerosis and myocardial infarction. The objective of this research is to develop therapeutic vaccines targeting IL-1R1 as a preventive measure against atherosclerosis and myocardial infarction.
METHODS: ILRQβ-007 and ILRQβ-008 vaccines were screened, prepared and then used to immunize high-fat-diet fed ApoE-/- mice and C57BL/6J mice following myocardial infarction. Progression of atherosclerosis in ApoE-/- mice was assessed primarily by oil-red staining of the entire aorta and aortic root, as well as by detecting the extent of macrophage infiltration. The post-infarction cardiac function in C57BL/6J mice were evaluated using cardiac ultrasound and histological staining.
RESULTS: ILRQβ-007 and ILRQβ-008 vaccines stimulated animals to produce high titers of antibodies that effectively inhibited the binding of interleukin-1β and interleukin-1α to IL-1R1. Both vaccines effectively reduced atherosclerotic plaque area, promoted plaque stabilization, decreased macrophage infiltration in plaques and influenced macrophage polarization, as well as decreasing levels of inflammatory factors in the aorta, serum, and ependymal fat in ApoE-/- mice. Furthermore, these vaccines dramatically improved cardiac function and macrophage infiltration in C57BL/6J mice following myocardial infarction. Notably, no significant immune-mediated damage was observed in immunized animals.
CONCLUSION: The vaccines targeting the IL-1R1 would be a novel and promising treatment for the atherosclerosis and myocardial infarction.
Repeated bouts of high-intensity interval training (HIIT) induce an improvement in metabolism via plasticity of melanocortin circuits and attenuated hypothalamic inflammation. HIF-1α, which plays a vital role in hypothalamus-mediated regulation of peripheral metabolism, is enhanced in the hypothalamus by HIIT. This study aimed to investigate the effects of HIIT on hypothalamic HIF-1α expression and peripheral metabolism in obese mice and the underlying molecular mechanisms. By using a high-fat diet (HFD)-induced obesity mouse model, we determined the effect of HIIT on energy balance and the expression of the hypothalamic appetite-regulating neuropeptides, POMC and NPY. Moreover, hypothalamic HIF-1α signaling and its downstream glycolytic enzymes were explored after HIIT intervention. The state of microglia and microglial NF-κB signaling in the hypothalamus were also examined in vivo. In vitro by using an adenovirus carrying shRNA-HIF1β, we explored the impact of HIF-1 signaling on glycolysis and NF-κB inflammatory signaling in BV2 cells. Food intake was suppressed and whole-body metabolism was improved in exercised DIO mice, accompanied by changes in the expression of POMC and NPY. Moreover, total and microglial HIF-1α signaling were obviously attenuated in the hypothalamus, consistent with the decreased levels of glycolytic enzymes. Both HFD-induced microglial activation and hypothalamic NF-κB signaling were significantly suppressed following HIIT in vivo. In BV2 cells, after HIF-1 complex knockdown, glycolysis and NF-κB inflammatory signaling were significantly attenuated. The data indicate that HIIT improves peripheral metabolism probably via attenuated HFD-induced microglial activation and microglial NF-κB signaling in the hypothalamus, which could be mediated by suppressed microglial HIF-1α signaling.
The invention discloses wild guava oral administration tablets capable of reducing blood sugar and resisting oxidation and a preparation method of the wild guava oral administration tablets. Each wild guava oral administration tablet comprises 50 parts of a wild guava extract, 10-20 parts of a filler, 8-15 parts of an adhesive, 2-5 parts of a disintegrant and 0.5-2 parts of a lubricant. After intragastric administration is performed on a mouse for 30 days through the oral administration tablets, the fasting blood sugar value of the mouse with diabetes induced by alloxan can restore to a value under a normal value of 7mmol/L, and besides, the activity of superoxide dismutase in mouse serum is improved. The preparation method comprises the following steps: using an acidic aqueous solution containing surface active substances for extracting wild guavas in a short time under the assistance of ultrasonic waves under lower temperature conditions so as to obtain active substances capable of reducing blood sugar and resisting oxidation, and then controlling reasonable parameters to prepare the oral administration tablet. The tablets contain rich protein and polysaccharide, so that a hypoglycemic reaction can be avoided. The tablets are small in size, small in dosage, and natural, safe and efficient, and can solve the problem that a dried guava chankings tea is low in utilization rate and poor in efficacy. The oral administration tablets have multiple efficacies of reducing the blood sugar, resisting oxidation, nutritional support and the like, and can provide a new selection for auxiliary treatment and nutritional health care of patients with diabetes.
<P>PROBLEM TO BE SOLVED: To provide a system and method for processing and analyzing virtual microscopy digital images ("virtual slides").  <P>SOLUTION: The system includes an algorithm server that maintains or has access to a plurality of image processing and image analysis routines. The algorithm server additionally has access to a plurality of virtual slides. The algorithm server executes a selected routine on an identified virtual slide and provides the resulting data. The virtual slide can be accessed locally or remotely through a network. Similarly, the image processing routines can be obtained from local storage or through a network, or both. Advantageously, certain common sub-routines may be stored locally so as to be included in other local or remotely obtained routines. Access to image processing and image analysis is restricted through a monitor process.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Preoperatively in the operation theater a tourniquet will be applied to the left arm and RIPC will performed. Therefore the tourniquet will be insufflated to suprasystolic pressure levels for 5 minutes, followed by 5 minutes reperfusion (deflated). Three cycles are planned. Duration of the procedure is 30 minutes.
Conventional open thyroid surgery is still one of the most common operations performed globally. Traditionally, patients who undergoing thyroid surgeries are usually positioned with extended neck by using pillow under shoulder in order to facilitate neck exposure and make the surgery easier. However, the degree of benefit from the extended neck is doubtful and there is little objective evidence that suggest extended neck thyroid surgery offers better outcomes. On the the hand, over-extension of the neck should be avoided because of it is associated with post-operative pain, vomiting, spinal damage and stroke. The objective of the present study is to compare the post-operative pain in patients with neck extension and without neck extension. In addition to that, we also like to determine the benefit of neck exposure and peri-operative complications, which include duration of operation, intra-operative blood loss, recurrent nerve (RLN) injury and hypocalcaemia in both groups. This is a prospective randomized controlled trial, which will be conducted from 1st of March 2012 till 30th September 2012. Given that approximately 300 to 400 patients would undergo thyroid surgery in each year, we estimated 180 patients will be recruited and randomly divided into 2 groups (neck extension and no neck extension) before undergoing open thyroid surgery for this trial. Visual analogue scale (VAS) is used to determine the post-operative pain. Primary end point and other peri-operative variables are then analyzed with SPSS software.
This is a pilot study that will be testing whether or not a group dance workshop is useful and effective. If it is, the study team will refine the workshop model and do additional dance classes in the future. This research study will involve attending a dance workshop once a week for 2 months using an online, video-conferencing computer application. Participants will also receive information about exercise and how to manage their diabetes. Participants will receive a phone call every week during the 2 months to assess their experience. Study participants will also be asked to complete surveys at the beginning and end of the 2-month session, as well as 1 month and 2 months after the classes end.
An erythropoietic factor is concentrated by contacting a solution of anaemic plasma with an ion exchange material and eluting the sorbed extract therefrom.  The ion exchange material may be an insoluble, substantially open-chain polymer such as a polysaccharide derivative; specified polysaccharides are starches (e.g. amylose and amylopectin), inulins, cellulose (e.g. a - and oxy-celluloses), xylans, pectine and algins, glycogens, chitins and muco polysaccharides (e.g. chondroitin sulphuric acid, heparin and hyaluronic acid), levans and dextrans.  Particularly preferred ion-exchangers are the anion-exchangers cellulose-dimethylaminoethyl- or diethylaminoethyl-ethers (prepared by condensing sodium cellulose with 2-chloroethyl-dimethylamine or -diethylamine respectively); carboxyf methylcellulose, cellulose citrate (esterification oan a -cellulose with citric acid) and cellulose phosphate are mentioned as cation-exchangers.  The anaemic plasma may be from ovine, bovine, porcine or other mammalian sources, but sheep plasma is preferred. The plasma solution preferably has a pH of 3.5-8.5, particularly 4.0-6.0, e.g. 4.2-4.8, and an alkali metal salt concentration of 0.01-0.06M, e.g. 0.03-0.04M NaCl (in the example NaH2PO4 is also present).  Elution is preferably effected with a 0.1-0.5M NaCl solution with a pH below 7.0.  Details are given of biological assay of the product.ALSO:An erythropoietic factor is concentrated by contacting a solution of anaemic plasma with an ion exchange material and eluting the sorbed extract therefrom.  The ion exchange material may be an insoluble, substantially open-chain polymer such as a polysaccharide derivative; specified polysaccharides are starches (e.g. amylose and amylopectin), inulins, cellulose (e.g. a - and oxy-celluloses), xylans, pectine and algins, glycogens, chitins and muco polysaccharides (e.g. chondroitin sulphuric acid, heparin and hyaluronic acid), levans and dextrans.  Particularly preferred ion-exchangers are the anion-exchangers cellulose-dimethylaminoethyl- or diethylaminoethyl-ethers (prepared by condensing sodium cellulose with 2-chloroethyl-dimethylamine or -diethylamine respectively); carboxymethylcellulose, cellulose citrate (esterification of an -cellulose with citric acid) and cellulose phosphate are mentioned as cation-exchangers.  The anaemic plasma may be from ovine, p  bovine, porcine or other mammalian sources, but sheep plasma is preferred. The plasma solution preferably has a pH of 3.5-8.5, particularly 4.0-6.0, e.g. 4.2-4.8, and an alkali metal salt concentration of 0.01-0.06 M, e.g. 0.03-0.04 M NaCl (in the example NaH2PO4 is also present).  Elution is preferably effected with a 0.1-0.5 M NaCl solution with a pH below 7.0.  Details are given of a biological assay of the product.
Treatment patterns in the community demonstrate that a substantial proportion of participants with bladder cancer do not receive curative intent therapy, especially if unfit for or refuse radical cystectomy. Concurrent chemoradiation is an accepted alternative to radical cystectomy, however systemic radio sensitizing chemotherapy may have significant off target side effects. This study is investigating the concurrent administration of a bladder cancer targeted antibody drug conjugate with radiotherapy. Sacituzumab govitecan (SG), or IMMU-132 is an investigational new drug that utilizes an antibody-drug conjugate (ADC) to target and kill epithelial bladder cancer cells. SG is experimental because it is not approved by the Food and Drug Administration (FDA) for use in this setting. The aim for this study is to establish the safety, tolerability, and feasibility of bladder preservation therapy treatment with concurrent SG and adaptive image-guided radiation therapy for platinum ineligible participants with localized MIBC.
Infertility is associated with severe psychological consequences; psychiatric disorders are common, particularly in women, yet current psychological interventions are not specialized to this population and are largely ineffective. The 7-week Coping with Infertility (CWI) program is a self-help program based on cognitive behaviour therapy that aims to improve mental health in women and individuals assigned female at birth who are experiencing infertility. This study aims to test the efficacy of the CWI program.

In the proposed study, a single-blind randomized controlled trial, participants will be randomly assigned to either the specialized CWI program or a waitlist/treatment as usual control condition using stratified block randomization. Infertility-related distress, quality of life, depression, anxiety, and relationship quality will be assessed at baseline, midway through the program, post-treatment, and biweekly for 16 weeks after treatment. It is expected that participants assigned to the CWI program will show significantly reduced infertility-related distress, depression, and anxiety, and improved quality of life and relationship quality relative to baseline and the waitlist control condition. Moderation analyses will examine potential treatment moderators including sexual orientation and gender identity, as well as cultural background, disability status, and whether participants are pursuing fertility treatments. Participants who complete the CWI program will also provide qualitative feedback on how the program can be improved. The results of this trial could establish the CWI program as an effective short-term therapy option for women experiencing infertility, addressing a significant gap in infertility treatment.
BACKGROUND: Lung ultrasound (LUS) has emerged as a useful tool in the acute phase of patients admitted for ST-segment-elevation myocardial infarction. However, its long-term significance remains uncertain, and risk scores do not include LUS findings as a predictor. This study aims to assess the 1-year prognostic value of LUS and its ability to enhance existing risk scores.
METHODS AND RESULTS: This is a multicenter prospective cohort study involving 373 patients with ST-segment-elevation myocardial infarction. LUS was performed during the first 24 hours after angiography. LUS results were assessed both as a categorical (wet/dry lung) and continuous variable (LUS score). The primary end point comprised the following major adverse cardiovascular events: all-cause mortality or hospitalization for heart failure, acute coronary syndrome, or stroke within 1 year. We also evaluated whether LUS could enhance the predictive value of the GRACE (Global Registry of Acute Coronary Events) score. Major adverse cardiovascular events occurred in 51 (13.7%) patients over a median follow-up of 368 days. After multivariate analysis, the LUS score was an independent predictor (hazard ratio [HR], 1.06 [95% CI, 1.01-1.10]; P=0.009] for each additional B-line), whereas the categorical classification was an independent predictor in patients with ST-segment-elevation myocardial infarction Killip I (HR, 3.12 [95% CI, 1.34-7.31]; P=0.009). Incorporating LUS into GRACE resulted in a net reclassification index of 31.6% and a significant increase in the area under the curve; GRACE alone scored 0.705 compared with GRACE+LUS 0.791 (P=0.002).
CONCLUSIONS: Detecting B-lines on LUS at the acute phase predicts major adverse cardiovascular events at 1 year in patients with ST-segment-elevation myocardial infarction and enhances the predictive value of the GRACE score. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04526535.
A slow-dissolving troche with polyol molecules is disclosed. It may be an adherent troche, preferably adhered to teeth or gums or cheek with acacia gum, or a lollipop or child's pacifier. Consumers are instructed to use the troches at the end of each day and after each meal, at least four times per day to benefit oral health, particularly caries, gingivitis, periodontitis, ear infections, sinus infections, halitosis and risk of Streptococcus mutans infecting their blood from their mouths. The polyol molecules are preferably xylitol. The troches may be made with a bi-layer tablet press rounded on one side and flat on the other, preferably using acacia gum in the flat side layer for adhesion. ® KIPO & WIPO 2009
HIV burden among adolescents and young people worldwide is substantial, with an estimated 1.7 million adolescents aged 10-19 years living with HIV in 2019, and 460,000 adolescents aged 15-24 newly infected reported in the same year. Adolescent girls continue to be disproportionately affected, accounting for 56% of new infections worldwide. With increased availability of antiretroviral therapy (ART), pediatric mortality has decreased and healthcare workers (HCW) are now challenged to meet the complex needs of the large number of surviving youth who must cope with HIV as a chronic, highly stigmatized, and transmittable illness. There are 1.8 billion people between ages 10 and 24 and it is projected that the number of people \<20 years will double by 2030. In sub-Saharan Africa (SSA), youth aged 10-24 years comprise 30-35% of the countries' population. Failure to prevent new HIV infections among adolescents will result in increased numbers of adolescents and young adults living with HIV (AYAHIV) who will strain health and social service systems as they transition to adulthood.